肝素对抗炎症:向演变和临床影响
1Research Institute, Changshan Biochemical Pharmaceutical, 71 Menglong Street, Zhengding New District, Shijiazhuang, 050800 Hebei, China.
Annales pharmaceutiques francaises
|December 3, 2025
概括
由于其复杂的结构,氨酸提供了超越抗凝药的广泛治疗潜力. 这一评论强调了肝素的重点.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
背景情况:
- 氨酸复杂的多糖结构使其能够与各种生物活性分子相互作用,从而产生超出抗凝作用的效果.
- 血栓炎症涉及复杂的相互作用,为新的治疗策略提供了机会.
- 氨酸的抗炎性质越来越被认可,这表明扩大了临床应用.
研究的目的:
- 为了提供一个全面的临床形象的炎症疾病受益于肝素.
- 探索肝素在治疗血栓炎症中的多方面的药理作用.
- 为了弥合肝素的生物机制与其在炎症条件下临床使用之间的差距.
主要方法:
- 临床数据和关于肝素在炎症疾病中的作用的科学文献的系统审查.
- 对肝素对抗血栓炎症的多向机制的分析.
- 汇编了用于治疗败血症,怀孕,肺部疾病,胰腺炎,病和皮肤疾病等疾病的肝素的证据.
主要成果:
- 氨酸在治疗一系列炎症状况方面具有显著的治疗潜力.
- 多种向机制有助于肝素的抗炎和抗血栓炎作用.
- 肝素在炎症症状中的临床应用正在扩大,尽管通常基于经验证据.
结论:
- 氨酸具有适用于各种炎症疾病的多方面的药理作用.
- 需要进一步的研究来充分阐明肝素的机制,并优化其用于治疗炎症的使用.
- 肝素代表了一种有前途的治疗药物,用于治疗血栓炎症和相关的炎症状况.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
265
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
265
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K


